Company news
TrivarX Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
MEB Signs Clinical Trial Agreement with MedBridge Healthcare
October 6, 2020
Request For FDA Breakthrough Device Designation Submitted
October 1, 2020
Patent Granted to Monitor Stress Conditions Using Heartrate
August 9, 2020
Entitlement Issue Results
July 9, 2020
Entitlement Offer Booklet
June 10, 2020
Placement and Fully Underwritten Entitlement Offer
June 9, 2020
Medibio submits FDA 510K Application to FDA
April 29, 2020
Final Compass Pilot Completed Successfully
April 8, 2020
Strategic Plan for FDA and CE Mark Approval
February 13, 2020
Company Update
December 8, 2019
Results of Annual General Meeting
November 22, 2019
Pause in Trading
November 21, 2019
Medibio Signs Agreement with PwC Australia for ilumen
October 23, 2019
MEB successfully completes first Ilumen pilot with Compass
October 20, 2019
Medibio Announces Results of Review of Partly Paid Shares
September 26, 2019
Fourth Pilot Agreement Signed with Compass Group for ilumen
August 30, 2019
Board Changes and Establishment of Advisory Board
August 29, 2019
MEB Signs Compass Group Australia to ilumen
July 29, 2019
MEB Partners with Corporate Wellness Solution Leader WellteQ
July 28, 2019
MEB Signs Second Compass Group PLC Pilot for ilumen
July 19, 2019
MEB Raises $4.02m via Placement and Fully Underwritten SPP
July 9, 2019
Suspension from Official Quotation
July 8, 2019
MEB Signs Compass Group to ilumen
June 30, 2019
Response to Appendix 4C Query
May 20, 2019
Regulatory and Commercialisation Strategy Update
April 29, 2019
Sponsored Research Agreement with Humanitas University
April 16, 2019
MEB Outsources Psychology Services in support of ilumen
March 13, 2019
Entitlement Issue Results and Shortfall Notification
March 12, 2019
Ilumen Successfully Completes First Commercial Program
March 6, 2019
Converting Note & Non-Renounceable Entitlement Offer
December 9, 2018
Exclusive Agreement Signed for ilumen Pilot Program
November 26, 2018
Response to ASX Appendix 4C Query
November 14, 2018
Medibio Provides Update on FDA Process
November 8, 2018
Medibio Appoints CEO and Managing Director
November 1, 2018
MEB Signs ilumen Contract with Large Australian Employer
October 23, 2018
Receipt of R&D Tax Incentive Refund
October 14, 2018
Medibio Releases Corporate Health Product, ilumen
October 3, 2018
Notice Received Under Section 249D of the Corporations Act
October 1, 2018
Executive Leadership Changes
September 20, 2018
Clinical Study Shows Improvement to Diagnostic Standard
September 5, 2018
Preliminary Final Report
August 29, 2018
Departure of Managing Director & Chief Executive Officer
August 28, 2018
Medibio Submits FDA De Novo Application
July 15, 2018
Medibio Receives TGA Approval
June 19, 2018
MEB Signs Global Contract with Jacobs Engineering
May 25, 2018
Medibio Announces Next Tranche of Corporate Health Contracts
May 9, 2018
Medibio Signs First Corporate Health Contract
May 8, 2018
Medibio Receives CE Certification
May 2, 2018
MEB signs binding term sheet to acquire Vital Conversations
March 4, 2018
Medibio Quarterly Update and Cash Flow Report
January 30, 2018
Decks
- JP Equity Partners 'Boom of the Biotech II' Investor Briefing (June 2026)
Conference · 17 slides · Jun 25, 2026
- TechKnow Invest Roadshow July 2024
Conference · 19 slides · Jul 30, 2024
- Investor Presentation (May 2024)
Investor deck · 16 slides · May 22, 2024
- Investor Presentation (November 2023)
Investor deck · 18 slides · Nov 16, 2023
- Shareholder Meeting (November 2020)
Shareholder meeting · 16 slides · Nov 12, 2020